CHICAGO — In this Healio Video Perspective from the AAO meeting, Constance O. Okeke, MD, MSCE, discusses a study that investigated the impact of latanoprostene bunod on IOP in patients with open-angle glaucoma and ocular hypertension.
“We’re really excited about this data because what it could mean is further support that switching from a [prostaglandin analog] or a non-combination PGA medication to latanoprostene bunod, or Vyzulta [Bausch + Lomb], can be very beneficial for helping to lower the eye pressure,” she said. “Notably, with patients who have a